ArticleMolecular cancer therapeutics2017
Wnt/β-catenin Signaling Contributes to Tumor Malignancy and Is Targetable in Gastrointestinal Stromal Tumor.
Open access · bronzeAbstract read
In one paragraph
Article in Molecular cancer therapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 39 citations in OpenAlex.
- Estrogen-related receptor alpha (ERRα) promotes gastrointestinal stromal tumor progression and epithelial-mesenchymal transition through Wnt/β-catenin.Research square · 2026Article
- A novel sulfonamide derivative suppresses gastrointestinal cancer progression by targeting Axin2 and β-catenin.Scientific reports · 2025Article
- Gene Mutations in Gastrointestinal Stromal Tumors: Advances in Treatment and Mechanism Research.Global medical genetics · 2024Review
- The pathogenic germline ETV4 P433L mutation identified in multiple primary lung cancer affect tumor stem-like property by Wnt/β-catenin pathway.Cell death & disease · 2024Article
- KIT mutations and expression: current knowledge and new insights for overcoming IM resistance in GIST.Cell communication and signaling : CCS · 2024Review
- Cellular Senescence, Inflammation, and Cancer in the Gastrointestinal Tract.International journal of molecular sciences · 2023Review
- Advances in immunology and immunotherapy for mesenchymal gastrointestinal cancers.Molecular cancer · 2023Review
- Risk-Related Genes and Associated Signaling Pathways of Gastrointestinal Stromal Tumors.International journal of general medicine · 2022Article
- Bile acids increase intestinal marker expression via the FXR/SNAI2/miR-1 axis in the stomach.Cellular oncology (Dordrecht, Netherlands) · 2021Article
- A literature review on function and regulation mechanism of DKK4.Journal of cellular and molecular medicine · 2021Review
- KAT6A, a novel regulator of β-catenin, promotes tumorigenicity and chemoresistance in ovarian cancer by acetylating COP1.Theranostics · 2021Article
- Tumor genotype, location, and malignant potential shape the immunogenicity of primary untreated gastrointestinal stromal tumors.JCI insight · 2020Article
- Aberrant accumulation of Dickkopf 4 promotes tumor progression via forming the immune suppressive microenvironment in gastrointestinal stromal tumor.Cancer medicine · 2019Article
- Differential immune profiles distinguish the mutational subtypes of gastrointestinal stromal tumor.The Journal of clinical investigation · 2019Article
- Tankyrase (PARP5) Inhibition Induces Bone Loss through Accumulation of Its Substrate SH3BP2.Cells · 2019Review
- CeRNA Expression Profiling Identifies KIT-Related circRNA-miRNA-mRNA Networks in Gastrointestinal Stromal Tumour.Frontiers in genetics · 2019Article
- The human adrenal cortex: growth control and disorders.Clinics (Sao Paulo, Brazil) · 2018Review
- The tankyrase inhibitor G007-LK inhibits small intestine LGR5Biological research · 2018Article
- Identification and Functional Characterization of Anti-metastasis and Anti-angiogenic Activities of Triethylene Glycol Derivatives.Frontiers in oncology · 2018Article
- ETV4 collaborates with Wnt/β-catenin signaling to alter cell cycle activity and promote tumor aggressiveness in gastrointestinal stromal tumor.Oncotarget · 2017Article
Corrections and comments
- Commented on by
Authors and funding
17 authors at 1 institution in 1 country.
Shan ZengDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Adrian M SeifertDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Jennifer Q ZhangDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Michael J CavnarDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Teresa S KimDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Vinod P BalachandranDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Juan A Santamaria-BarriaDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Noah A CohenDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Michael J BeckmanDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Benjamin D MedinaDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Ferdinand RossiDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Megan H CrawleyDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Jennifer K LooDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Joanna H MaltbaekDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Peter BesmerDepartment of Developmental Biology, Memorial Sloan Kettering Cancer Center, New York, New York.
Cristina R AntonescuDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Ronald P DeMatteoDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York. dematter@mskcc.org.
Memorial Sloan Kettering Cancer Center · US
Funding
SPORE in Soft Tissue SarcomaP50CA140146 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI QIN, LI-XUAN · 2010 to 2014
$11.1MMolecular Mechanisms in Gastrointestinal Stromal TumorR01CA102613 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Ronald P. Dematteo · 2004 to 2026
$9.2MSURGICAL ONCOLOGY RESEARCH TRAINING PROGRAMT32CA009501 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Babak J Mehrara · 1985 to 2026
$7.7MTyrosine kinase inhibition and immunomodulation for cancerF32CA186534 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ZHANG, JENNIFER Q · 2014 to 2015
$109kAnti-CTLA-4 enhances the effects of imatinib in gastrointestinal stromal tumorF32CA162721 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI KIM, TERESA SORA · 2011 to 2012
$109kNCI NIH HHS F32 CA162721NCI NIH HHS F32 CA186534NCI NIH HHS P50 CA140146NCI NIH HHS R01 CA102613NCI NIH HHS T32 CA009501
Abstract
Gastrointestinal stromal tumor (GIST) is the most common type of sarcoma and usually harbors either a
Indexed as
Wnt Signaling PathwayAnimalsAntineoplastic Agentsbeta CateninCell Line, TumorDisease Models, AnimalGastrointestinal Stromal TumorsHumansImatinib MesylateIntercellular Signaling Peptides and ProteinsMiceMice, TransgenicMolecular Targeted TherapyNeoplasm GradingNeoplasm StagingUbiquitin-Protein LigasesAntineoplastic Agentsbeta CateninCOP1 protein, humanDKK4 protein, humanImatinib MesylateIntercellular Signaling Peptides and ProteinsUbiquitin-Protein LigasesWnt3A Protein
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.